Lindner, I.I.LindnerHemdan, N.Y.A.N.Y.A.HemdanBuchold, M.M.BucholdHuse, K.K.HuseBigl, M.M.BiglOerlecke, I.I.OerleckeRicken, A.A.RickenGaunitz, F.F.GaunitzSack, U.U.SackNaumann, A.A.NaumannHollborn, M.M.HollbornThal, D.D.ThalGebhardt, R.R.GebhardtBirkenmeier, G.G.Birkenmeier2022-03-042022-03-042010https://publica.fraunhofer.de/handle/publica/22188710.1158/0008-5472.CAN-09-1462Targets that could improve the treatment of brain tumors remain important to define. This study of a transformation-associated isoform of alpha 2-macroglobulin (A2M*) and its interaction with the low-density lipoprotein receptor-related protein-1 (LRP1) suggests a new mechanism for abrogating the malignant potential of astrocytoma cells. LRP1 bound A2M* found to be associated with an inhibition of tumor cell proliferation, migration, invasion, spheroid formation, and anchorage-independent growth. Transcriptional studies implicated effects on the Wnt/beta-catenin signaling pathway. Notably, LRP1 antibodies could phenocopy the effects of A2M*. Our findings suggest a pathway of tumor suppression in astrocytoma that might be tractable to therapeutic exploitation.ena2-macroglobulinhuman 1321N1 astrocytoma cellsLRP1Wnt/ß-catenin pathwayglioma610616journal article